Cargando…

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study

OBJECTIVE: Large‐scale epidemiological studies have demonstrated a protective effect of clozapine on mortality in people with schizophrenia. Clozapine is reserved for use in patients with treatment‐resistant schizophrenia (TRS), but evidence of clozapine's effect on mortality exclusively within...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, J., Hayes, R. D., Jewell, A., Kadra, G., Shetty, H., MacCabe, J. H., Downs, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492259/ https://www.ncbi.nlm.nih.gov/pubmed/30478891 http://dx.doi.org/10.1111/acps.12989

Ejemplares similares

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records
por: de Freitas, Daniela Fonseca, et al.
Publicado: (2022)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
por: Govind, Risha, et al.
Publicado: (2022)

Ethnic inequalities in treatment with clozapine
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Reasons for discontinuing clozapine: A cohort study of patients commencing treatment
por: Legge, Sophie E., et al.
Publicado: (2016)

Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2016)

Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality
por: Kadra, G., et al.
Publicado: (2018)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Sendt, Kyra-Verena, et al.
Publicado: (2018)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
por: McQueen, Grant, et al.
Publicado: (2021)

Biological Predictors of Clozapine Response: A Systematic Review
por: Samanaite, Ruta, et al.
Publicado: (2018)

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

Clozapine treatment and risk of severe COVID‐19 infection
por: Ohlis, Anna, et al.
Publicado: (2021)

A predictor model of treatment resistance in schizophrenia using data from electronic health records
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit
por: Barnes, Thomas RE, et al.
Publicado: (2022)

Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis
por: Shirazi, Ayala, et al.
Publicado: (2016)

The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders
por: Hayes, Richard D., et al.
Publicado: (2015)

Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia
por: Krajner, Fanni, et al.
Publicado: (2022)

Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
por: Kadra, Giouliana, et al.
Publicado: (2015)

Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services
por: Barnes, Thomas R. E., et al.
Publicado: (2020)

Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies
por: Smart, S. E., et al.
Publicado: (2021)

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
por: Blackman, Graham, et al.
Publicado: (2021)

Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review
por: Gillespie, Amy L., et al.
Publicado: (2017)

Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study
por: Johannsen, Claas-Frederik, et al.
Publicado: (2022)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_48khhlmj9aln4724p2v2vqc90i